Prevalence of resistance mutations in antiretroviralnaive chronically HIV-infected patients in 1998: A French nationwide study

AIDS

Volumn 15, Issue 14, 2001, Pages 1777-1782

  Descamps, Diane ^a   Calvez, Vincent ^b   Izopet, Jacques ^c   Buffet Janvresse, Claudine ^d   Schmuck, Anne ^e   Colson, Philippe ^f   Ruffault, Annick ^g   Maillard, Anne ^h   Masquelier, Bernard ⁱ   Cottalorda, Jacqueline ^j   Harzic, Martine ^k   Brun Vézinet, Françoise ^a   Costagliola, Dominique ^l  

^a BICHAT HOSPITAL   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c CHU PURPAN   (France)

^d HÔPITAL CHARLES NICOLLE   (France)

^e Vascular Surgery Department   (France)

^f Hôpital de Ia Timone   (France)

^g PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

^h SAINT LOUIS HOSPITAL   (France)

ⁱ HÔPITAL PELLEGRIN   (France)

^j Hôpital de Nice   (France)

^k CENTRE HOSPITALIER DE VERSAILLES   (France)

^l NONE

more..

Author keywords

HIV; Mutations; Prevalence; Primary resistance; Protease inhibitors; Reverse transcriptase inhibitors

Indexed keywords

PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ARTICLE; FEMALE; FRANCE; GENE MUTATION; GENOTYPE; HEALTH SURVEY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; VIRUS RESISTANCE;

ADULT; ANTI-HIV AGENTS; CHRONIC DISEASE; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; MALE; PHYLOGENY; PREVALENCE; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 0035964692     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200109280-00005     Document Type: Article

References (36)

1. Antiretroviral therapy for HIV infection in 1998
2. Decay characteristics of HIV-1-infected compartments during combination therapy
3. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy
4. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less
5. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
6. Multiple concurrent reverse transcriptase and protease mutations and multidrug resistance of HIV-1 isolates from heavily treated patients
7. Mutations in retroviral genes associated in drug resistance
8. Virological and clinical implications of resistance to HIV-1 protease inhibitors
9. Virological treatment failure of protease inhibitor therapy in an unselected cohort of HIV-infected patients
10. HIV-1 RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: Response to both initial and salvage therapy
11. Primary infection with zidovudine-resistant human immunodeficiency virus type 1
12. Transmission of human immunodeficiency virus type 1 resistant to nevirapine and zidovudine
13. Sexual transmission of an HIV-1 variant resistant to multiple reverse-transcriptase and protease inhibitors
14. Transmission of antiretroviral-drug-resistant HIV-1 variants
15. HIV-1 drug resistance in newly infected individuals
16. Reduced antiretroviral drug susceptibility among patients with primary infection
17. Prevalence of HIV-1 resistant to antiretroviral drugs in 81 individuals newly infected by sexual contact or injecting drug use
18. Transmission of multidrug-resistant human immunodeficiency virus the wake-up call
19. Prevalence of genotypic drug resistance among French patients infected during the year 1999
20. Public health implications of antiretroviral therapy and HIV drug resistance
21. Antiretroviral drug resistance testing in adult HIV-1 infection. Recommendations of an International AIDS Society - USA Panel
22. HIV-1 subtyping using phylogenetic analysis of pol gene sequences
23. CLUSTAL W: Improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice
24. Estimating means and percentages in a complex sampling survey: Application to a French national survey on sexual behaviour (ACSF)
25. Factors associated with clinical and virological failure in patients receiving a triple therapy including a protease inhibitor
26. The prevalence of PI, NRTI and NNRTI resistance-associated mutations in a large ARV-naive, European cross-sectional population: A baseline analysis of the SERVICE project
27. Prevalence of phenotypic and genotypic resistance in recently infected antiretroviral inexperienced patients: The German HIV Research Initiative Cohort
28. Prevalence of mutations associated with antiretroviral drug resistance among drug naive persons recently diagnosed with HIV-1, USA 1997-1999
29. Primary genotype resistance in HIV naive patients in valencian community (Spain): The Recova Study
30. An epidemiological prospective survey assessing the prevalence of HIV-1 drug resistance in 230 HIV-1 positive antiretroviral-naive patients from the USA
31. Polymorphism of the human immunodeficiency virus type 1 (HIV-1) protease gene and response of HIV-1 infected patients to a protease inhibitor
32. Virologic and immunologic evaluation of structured treatment interruption (STI) in patients experiencing a long-term virologic failure
33. Rapid decline in detectability of HIV-1 drug resistance mutations after stopping therapy
34. Switch to unusual amino acids at codon 215 of the human immunodeficiency virus type 1 reverse transcriptase gene in seroconvertors infected with zidovudine-resistant variants
35. Replicative fitness of protease inhibitor-resistant mutants of human immunodeficiency virus type 1
36. Retracing the evolutionary pathways of human immunodeficiency virus type 1 resistance to protease inhibitors: Virus fitness in the absence and in the presence of drug